Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics

Therapeutic Delivery

Volumn 6, Issue 4, 2015, Pages 469-490

  Tatham, Lee M ^a   Rannard, Steven P ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DENDRIMER; EFAVIRENZ; LOPINAVIR; NANOCARRIER; NANOPARTICLE; RITONAVIR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; TENOFOVIR; DELAYED RELEASE FORMULATION;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; ENDOCYTOSIS; GASTROINTESTINAL ABSORPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; PHYSICAL CHEMISTRY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SUSPENSION; BIOAVAILABILITY; DELAYED RELEASE FORMULATION; HIV INFECTIONS; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; THERAPEUTIC USE;

ADMINISTRATION, ORAL; ANTI-RETROVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL ABSORPTION; HIV INFECTIONS; HUMANS; NANOMEDICINE;

EID: 84929721060     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.4     Document Type: Review

References (143)

1. World Health Organisation. www.who.int
2. Holtgrave DR. Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both? Int. J. STD AIDS 16, 777-781 (2005).
3. Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK. Nanotechnology: A magic bullet for HIV AIDS treatment. Artif. Cells Nanomed. Biotechnol. (2014) (Epub ahead of print).
4. Mamo T, Moseman EA, Kolishetti N et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond.) 5, 269-285 (2010).
5. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomedicine 5, 533-547 (2010).
6. Tinkle S, McNeil SE, Mühlebach S et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci. 1313, 35-56 (2014).
7. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M, Consortium N. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond.) 8, 449-467 (2013).
8. Irache JM, Esparza I, Gamazo C, Agüeros M, Espuelas S. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet. Parasitol. 180, 47-71 (2011).
9. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Deliv. Rev. 62, 491-502 (2010).
10. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 11, 740-746 (2009).
11. Date AA, Destache CJ. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 34, 6202-6228 (2013).
12. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16-20 (2009).
13. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58, 173-182 (2004).
14. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. Drug Discov. Today 9, 87-95 (2012).
15. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39, 211-238 (1999).
16. Serajuddin AT. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59, 603-616 (2007).
17. Akers MJ. Excipient-Drug interactions in parenteral formulations. J. Pharm. Sci. 91, 2283-2300 (2002).
18. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16, 354-360 (2011).
19. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5, 496-504 (2008).
20. Neves JD, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 62, 458-477 (2010).
21. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (Lond.) 5, 11-23 (2010).
22. Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 39, 105-116 (1999).
23. Shibata A, McMullen E, Pham A et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res. Hum. Retroviruses 29, 746-754 (2013).
24. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54, 759-779 (2002).
25. Alvarez-Lorenzo C, Rey-Rico A, Brea J, Loza MI, Concheiro A, Sosnik A. Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: branched versus linear derivatives. Nanomedicine (Lond.) 5, 1371-1383 (2010).
26. Dutta T, Garg M, Jain NK. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 34, 181-189 (2008).
27. Hrkach J, Von Hoff D, Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128-139 (2012).
28. Chiappetta DA, Hocht C, Opezzo JA, Sosnik A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.) 8, 223-237 (2013).
29. Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv. 21, 148-154 (2014).
30. Puligujja P, McMillan J, Kendrick L et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 9, 1263-1273 (2013).
31. Gautam N, Roy U, Balkundi S et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57, 3110-3120 (2013).
32. Nowacek AS, Balkundi S, McMillan J et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control. Release 150, 204-211 (2011).
33. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453, 198-214 (2013).
34. Zhang L, Wang S, Zhang M, Sun J. Nanocarriers for oral drug delivery. J. Drug Target 21, 515-527 (2013).
35. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine 8(1), 5-20 (2012).
36. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv. Drug Deliv. Rev. 63, 901-908 (2011).
37. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 60, 702-716 (2008).
38. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang Sinko PJ. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 62, 518-531 (2010).
39. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593 (2002).
40. Macal M, Sankaran S, Chun TW et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 1, 475-488 (2008).
41. des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert V, Préat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65, 833-844 (2013).
42. Dolgin E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat. Med. 20, 323-324 (2014).
43. Spreen W, Min S, Ford SL et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin. Trials. 14, 192-203 (2013).
44. Spreen W, Ford SL, Chen S et al. GSK1265744 Pharmacokinetics in plasma and tissue following single-dose long-acting (LA) injectable administration in healthy subjects. J. Acquir. Immune Defic. Syndr. 67(5), 481-486 (2014).
45. Andrews CD, Spreen WR, Mohri H et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343, 1151-1154 (2014).
46. Freeling JP, Ho RJ. Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence. Proc. Natl Acad. Sci. USA 111, E2512-E2513 (2014).
47. Duan J, Freeling JP, Koehn J, Shu C, Ho RJ. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J. Pharm. Sci. 103, 2520-2529 (2014).
48. Williams J, Sayles HR, Meza JL et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond.) 8, 1807-1813 (2013).
49. Giaquinto C, Morelli E, Fregonese F et al. Current and future antiretroviral treatment options in paediatric HIV infection. Clin. Drug Invest. 28, 375-397 (2008).
50. Sosnik A, Carcaboso AM. Nanomedicines in the future of pediatric therapy. Adv. Drug Deliv. Rev. 73, 140-161 (2014).
51. Chiappetta DA, Alvarez-Lorenzo C, Rey-Rico A, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. Eur. J. Pharm. Biopharm. 76, 24-37 (2010).
52. Chiappetta DA, Facorro G, de Celis ER, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine 7, 624-637 (2011).
53. Moretton MA, Taira C, Flor S et al. Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation. Colloids Surf. B Biointerfaces 23, 302-310 (2014).
54. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64, 557-570 (2012).
55. Johansson ME, Ambort D, Pelaseyed T et al. Composition and functional role of the mucus layers in the intestine. Cell. Mol. Life Sci. 68, 3635-3641 (2011).
56. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 4, 488-520 (2012).
57. Woitiski CB, Neufeld RJ, Veiga F, Carvalho RA, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci. 41, 556-563 (2010).
58. Liu Y, Chiu GN. Dual-functionalized PAMAM dendrimers with improved P-glycoprotein inhibition and tight junction modulating effect. Biomacromolecules 14, 4226-4235 (2013).
59. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin. Gastroenterol. Hepatol. 12(10), 1605-1610 (2014)
60. Gaumet M, Gurny R, Delie F. Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity. Int. J. Pharm. 390, 45-52 (2010).
61. Shahbazi MA, Santos HA. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr. Drug Metab. 14, 28-56 (2013).
62. Salamat-Miller N, Johnston TP. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294, 201-216 (2005).
63. Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190, 485-499 (2014).
64. Tuma P, Hubbard, AL. Transcytosis: crossing cellular barriers. Physiol. Rev. 83, 871-932 (2003).
65. Gullberg ELM, Karlsson J, Hopkins AM, Brayden D, Baird AW, Artursson P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279, 808-813 (2000).
66. Beloqui A, Solinís M, Gascón AR, del Pozo-RodrÃ-guez A, des Rieux A, Préat V. Mechanism of transport of saquinavirloaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166, 115-123 (2013).
67. He B, Lin P, Jia Z et al. The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34, 6082-6098 (2013).
68. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116, 1-27 (2006).
69. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Control. Release 145, 182-195 (2010).
70. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol. Biol. 440, 15-33 (2008).
71. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159-169 (2004).
72. des Rieux A, Fievez V, Théate I, Mast J, Préat V, Schneider YJ. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30, 380-391 (2007).
73. Kitchens KM, Foraker AB, Kolhatkar RB, Swaan PW, Ghandehari H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24, 2138-2145 (2007).
74. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond.) 5, 287-306 (2010).
75. Nkansah P, Antipas A, Lu Y et al. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. J. Control. Release 169, 150-161 (2013).
76. Yao M, Xiao H, McClements DJ. Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles. Annu. Rev. Food Sci. Technol. 5, 53-81 (2014).
77. Abuasal BS, Lucas C, Peyton B et al. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids 47, 461-469 (2012).
78. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36, 43-48 (2008).
79. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364, 64-75 (2008).
80. McDonald TO, Giardiello M, Martin P et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv. Healthc. Mater. 3, 400-411 (2014).
81. Jain S, Sharma JM, Jain AK, Mahajan RR. Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine (Lond.) 8, 1639-1655 (2013).
82. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 42, 11-18 (2011).
83. Negi JS, Chattopadhyay P, Sharma AK, Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur. J. Pharm. Sci. 48, 231-239 (2013).
84. Ravi PR, Vats R, Dalal V, Gadekar N. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Drug Dev. Ind. Pharm. 41(1), 131-140 (2013).
85. Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 347, 93-101 (2008).
86. Kotta S, Khan AW, Ansari SH, Sharma RK, Ali J. Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. Int. J. Pharm. 462, 129-134 (2014).
87. Beloqui A, Solinís M, des Rieux A, Préat V, Rodríguez-Gascón A. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int. J. Pharm. 468, 105-111 (2014).
88. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796 (2004).
89. McDonald TO, Martin P, Patterson JP et al. Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. Adv. Funct. Mater. 22, 2469-2478 (2012).
90. Zhang H, Wang D, Butler R et al. Formation and enhanced biocidal activity of water-dispersable organic nanoparticles. Nat. Nanotechnol. 3, 506-511 (2008).
91. Siccardi M, Martin P, McDonald TO et al. Nanomedicines for HIV therapy. Ther. Deliv. 4, 153-156 (2013).
92. Owen A, Khoo, SH. Intracellular pharmacokinetics of antiretroviral agents. J. HIV Ther. 9, 97-101 (2004).
93. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther. Clin. Risk Manag. 4, 1023-1033 (2008).
94. Zhou S, Chan E, Lim LY et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 5, 415-442 (2004).
95. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin. Drug Deliv. 8, 1407-1424 (2011).
96. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 62, 1637-1645 (2010).
97. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
98. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34, 1394-1405 (2008).
99. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol. 7, 41-55 (2013).
100. McClements DJ. Nanoemulsion-based oral delivery systems for lipophilic bioactive components: nutraceuticals and pharmaceuticals. Ther. Deliv. 4, 841-857 (2013).
101. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behaviour in vitro and in vivo. J. Control. Release 119, 77-85 (2007).
102. Sahana DK, Mittal G, Bhardwaj V, Kumar MN. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behaviour in vitro and in vivo using estradiol as a model drug. J. Pharm. Sci. 97, 1530-1542 (2008).
103. Meena AK, Ratnam DV, Chandraiah G, Ankola DD, Rao PR, Kumar MN. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia. Lipids 43, 231-241 (2008).
104. Spitzenberger TJ, Heilman D, Diekmann C et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 27, 1033-1042 (2007).
105. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
106. Ould-Ouali L, Noppe M, Langlois X et al. Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J. Control. Release 102, 657-668 (2005).
107. Yi Y, Yoon HJ, Kim BO et al. A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. J. Control. Release 117, 59-67 (2007).
108. Gao JZ, Hussain MA, Motheram R et al. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water-soluble/highly permeable drug (efavirenz). J. Pharm. Sci. 96,2970-2977 (2007).
109. Chiappetta DA, Hocht C, Taira C, Sosnik A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 32, 2379-2387 (2011).
110. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 71, 445-462 (2009).
111. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57, 2177-2202 (2005).
112. Tomalia D. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanosacle synthetic polymer chemistry. Prog. Polym. Sci. 30, 294-324 (2005).
113. Biricova V, Laznickova A. Dendrimers: analytical characterization and applications. Bioorg. Chem. 37, 185-192 (2009).
114. Weber N, Ortega P, Isabel Clemente M et al. Characterisation of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control. Release 132, 55-64 (2008).
115. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv. Drug Deliv. Rev. 64, 571-588 (2012).
116. Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm. Res. 25, 1723-1729 (2008).
117. Ke W, Zhao Y, Huang R, Jiang C, Pei Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci. 97, 2208-2216 (2008).
118. Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 8,3853-3859 (2007).
119. Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J. Control. Release 147, 62-69 (2010).
120. Hatton FL, Chambon P, McDonald TO, Owen A, Rannard SP. Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. Chem. Sci. 5,1844-1853 (2014).
121. Hatton FL, Tatham LM, Tidbury LR et al. Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. Chem. Sci. 6, 326-334 (2015).
122. Gupta SK Nutan. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl.) 5, 295-307 (2013).
123. Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res. 99, 391-400 (2013).
124. Van Damme L, Corneli A, Ahmed K et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012).
125. Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J. Control. Release 190, 500-514 (2014).
126. Telwatte S, Moore K, Johnson A et al. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiv. Res. 90, 195-199 (2011).
127. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2, 561-566 (2007).
128. Sharpe LA, Daily AM, Horava SD, Peppas NA. Therapeutic applications of hydrogels in oral drug delivery. Expert Opin. Drug Deliv. 11, 901-915 (2014).
129. Li J, Li X, Kuang Y et al. Self-delivery multifunctional anti-HIV hydrogels for sustained release. Adv. Healthc. Mater. 2, 1586-1590 (2013).
130. Sundara Rajan S, Cavera VL, Zhang X, Singh Y, Chikindas ML, Sinko PJ. Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis. Antimicrob. Agents Chemother. 58, 2747-2753 (2014).
131. van't Klooster G, Hoeben E, Borghys H et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 54, 2042-2050 (2010).
132. Baert L, van't Klooster G, Dries W et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72, 502-508 (2009).
133. Yoshinaga T, Kobayashi M, Seki T et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob. Agents Chemother. 59, 397-406 (2015).
134. Cohen J. Virology. A bid to thwart HIV with shot of long-lasting drug. Science 343, 1067 (2014).
135. Balkundi S, Nowacek, AS, Veerubhotla RS et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int. J. Nanomedicine 6, 3393-3404 (2011).
136. Kadiu I, Nowacek A, McMillan J, Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond.) 6, 975-994 (2011).
137. Chun TW, Murray D, Justement JS et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc. Natl Acad. Sci. USA 111, 13151-13156 (2014).
138. Walker LM, Huber M, Doores KJ et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
139. Barouch DH, Whitney JB, Moldt B et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
140. Horwitz JA, Halper-Stromberg A, Mouquet H et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).
141. Huang J, Kang BH, Pancera, M et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142 (2014).
142. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int. J. Nanomedicine 9, 1005-1023 (2014).
143. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in-vitro and in-vivo immunotoxicity tests for nanomedicines. J. Control. Release 172, 456-466 (2013).